London-listed IQ-AI (AIM:IQAI) says its subsidiary, Imaging Biometrics, has entered into a global distribution agreement with AI Metrics.
Under the deal, Imaging Biometrics (IB) will be granted non-exclusive global rights to market AI Metrics’ image analysis product, LSN.
The LSN software acts as a virtual liver biopsy and assesses Chronic Liver Disease (CLD), a disease responsible for over 20 million deaths worldwide.
By assessing nodules or bumps on the liver’s surface, the technology can aid clinicians in the diagnosis and staging of the disease with a low risk assessment using CT images.
IB have been working closely with AI Metrics’ Chief Executive Dr Andrew Smith to develop the LSN software in the lead up to the deal.
"We are excited about partnering with Imaging Biometrics as we introduce LSN technology to the worldwide market," said Smith.
He added that the partnership would ensure wider utilisation of the technology and highlighted this development as critical for the transition of LSN from “promising research to commercial introduction.”
Currently, IB is assisting AI Metrics to obtain a CE mark and clearance from the FDA to allow LSN to be marketed in Europe and the US respectively.
"LSN fits perfectly with IB's product portfolio and we look forward to helping deploy LSN worldwide," said Michael Schmainda, Director of IB.
He added, “The ability to non-invasively and accurately assess CLD is exciting for clinicians and will ultimately benefit patients.”
Follow News & Updates from IQ-AI here: